BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32228295)

  • 21. Uterine serous carcinoma: assessing association between genomics and patterns of metastasis.
    Alessandrino F; Goncalves N; Metalonis SW; Luna C; Mason MM; Lyu J; Huang M
    Front Oncol; 2023; 13():1066427. PubMed ID: 37228503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
    Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
    Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
    Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
    Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
    Sangster AG; Gooding RJ; Garven A; Ghaedi H; Berman DM; Davey SK
    PLoS One; 2022; 17(1):e0259992. PubMed ID: 35073341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
    Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
    PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.
    Shinagare AB; Ramaiya NH; Jagannathan JP; Fennessy FM; Taplin ME; Van den Abbeele AD
    AJR Am J Roentgenol; 2011 Jan; 196(1):117-22. PubMed ID: 21178055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.
    Zareba P; Rosenzweig B; Winer AG; Coleman JA
    Cancer; 2017 May; 123(10):1741-1750. PubMed ID: 28152158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
    Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
    BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
    Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
    J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma.
    Kim HS; Ku JH; Jeong CW; Kwak C; Kim HH
    World J Urol; 2016 Jun; 34(6):859-69. PubMed ID: 26497823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma.
    Aboumohamed AA; Krane LS; Hemal AK
    J Urol; 2015 Dec; 194(6):1561-6. PubMed ID: 26192256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genetic analysis results of patients with a retinoblastoma refractory to systemic chemotherapy].
    Ruiz del Río N; Abelairas Gómez JM; Alonso García de la Rosa FJ; Peralta Calvo JM; de las Heras Martín A
    Arch Soc Esp Oftalmol; 2015 Sep; 90(9):414-20. PubMed ID: 25817468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
    Fontana LO; García García F; Arcas Martínez Salas I; García Ligero J; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Canteras Jordana M
    Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience.
    Cutress ML; Stewart GD; Tudor EC; Egong EA; Wells-Cole S; Phipps S; Thomas BG; Riddick AC; McNeill SA; Tolley DA
    J Urol; 2013 Jun; 189(6):2054-60. PubMed ID: 23228378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.